Navigation Links
Sangamo BioSciences Announces Fourth Quarter and Full Year 2009 Conference Call and Webcast
Date:1/27/2010

g proteins for therapeutic gene regulation and modification.  The most advanced ZFP Therapeutic™ development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS and another Phase 1 trial to evaluate safety and clinical effect of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.  Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification.  Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's web site at http://www.sangamo.com/.

SOURCE Sangamo BioSciences, Inc.

RELATED LINKS
http://www.sangamo.com

'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
2. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
3. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
4. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
5. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
6. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
7. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
8. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
9. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
10. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
11. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... CHICAGO, Ill. , Sept. 19, 2014  The ... ABBV ) declared a quarterly cash dividend of $0.42 ... payable Nov. 17, 2014 to stockholders of record at ... About AbbVie AbbVie is a global, research-based biopharmaceutical ... company,s mission is to use its expertise, dedicated people ...
(Date:9/19/2014)... STATION, N.J. , Sept. 19, 2014 Merck (NYSE: ... United States and Canada , is ... Desafiando La Diabetes: Logra Tus Metas , an educational program ... their blood sugar -- a key treatment goal to help reduce ... United States are at a higher risk for developing ...
(Date:9/19/2014)... 2014 Larry J. Merlo , President and ... speak before the National Press Club in Washington, ... move to stop selling tobacco products and its leadership in ... "Dramatic changes in our health care system pose ... Merlo has said. "CVS Health has a truly unique combination ...
Breaking Medicine Technology:Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3
... PASADENA, Calif.--(BUSINESS WIRE)--Jun 20, 2007 - Materia, ... licensing of its,metathesis platform to Eisai Co., ... in drug discovery and development.,The non-exclusive license ... pharmaceutical compounds and related processes,using the Company's ...
... 2007 - VIVUS, Inc.,(NASDAQ: VVUS), a pharmaceutical ... novel therapeutic products,announced that Abstract #2209-PO, Evaluation ... with Phentermine and Topiramate:,Outcomes in a Private ... Diabetes Association 2007 Scientific Sessions Abstract,book. The ...
Cached Medicine Technology:Materia Licenses Metathesis Catalyst Platform to Eisai 2VIVUS Announces Abstract Published at American Diabetes Association,Scientific Sessions 2VIVUS Announces Abstract Published at American Diabetes Association,Scientific Sessions 3
(Date:9/21/2014)... To accommodate the ever-growing customer base, Angeldress.co.uk decided to ... Recently, the company has unveiled its 2014 vintage ... wedding gowns, Angeldress.co.uk wants to make sure that all ... way. Its high quality vintage wedding outfits are now ... 62% off. , Online shopping is becoming more and ...
(Date:9/21/2014)... September 21, 2014 “Cluster headaches are ... intense and difficult to resolve,” said Steve Young of ... think of a pain that is more intense.” , ... from cluster headaches, or migraines, that medical research is ... serotonin system,” he added. , Serotonin (5-HT, 5-hydroxytryptamine) is ...
(Date:9/21/2014)... C8 lawsuits move forward in the U.S. ... of 20 possible C8 lawsuits selected for bellwether ... Wright & Schulte LLC. Court records show these six ... lawsuits filed that represent individuals who purportedly developed kidney ... of being exposed to water contaminated by the C8 ...
(Date:9/20/2014)... Recently, UWDress.com, a professional company of women’s dresses ... newly announced evening cocktail dresses . As a ... outfits are very popular among worldwide customers. Now, all ... (up to 65 percent off). , All UWDress.com’s ... occasion outfits for the global clients. The company is ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 David Cooke ... 2014. The first poster looked at the clinical benefits ... cycle for calculating diastolic function. In conjunction with colleagues ... renal disease and normal LVEF by echo (>50%). Each ... protocol, and standard SPECT. Emory Toolbox 4.0 ...
Breaking Medicine News(10 mins):Health News:Angeldress.co.uk Launches New Range Of 2014 Vintage Wedding Dresses In Its Online Store 2Health News:Homeostasis: Equinox Serotonin (5HT) Headache Stories ~ New on the Bryan William Brickner Blog 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 3Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 4Health News:Cheap Evening Cocktail Dresses Recently Introduced At UWDress.com 2Health News:Versatility of Emory Toolbox 4.0 Shown at ASNC in Scientific Posters 2Health News:Versatility of Emory Toolbox 4.0 Shown at ASNC in Scientific Posters 3
... Jenifer Goodwin HealthDay Reporter , MONDAY, Aug. ... marijuana, reduced pain in patients with nerve pain stemming ... Twenty-one adults with chronic nerve pain were taught to ... through a pipe, three times a day, for five ...
... When given a choice, older people prefer to read negative news, ... In fact, older readers who chose to read negative stories ... according to the results. And what about younger people? Well, ... results come from a study of 276 Germans who were asked ...
... growing epidemic of the world,s most common heart rhythm ... admissions in Australia, according to cardiology researchers. A ... University of Adelaide and the Cardiovascular Research Centre at ... to atrial fibrillation had more than tripled in Australia ...
... Children,s Hospital finds visits to emergency departments for concussions ... over a 10-year period, and appear to be highest ... concussions is highest in high school-aged athletes, but the ... study is published in the September 2010 issue of ...
... By Jenifer Goodwin HealthDay Reporter , SUNDAY, ... a gene on chromosome 8 may raise the risk of ... been believed to have a genetic component, pinpointing specific genes ... is among the first to identify a specific genetic variant ...
... who will develop tuberculosis, as scientists have identified changes ... are from an international study published in the August ... doctors and researchers at Nationwide Children,s Hospital using blood ... is caused by the bacterium Mycobacterium tuberculosis, which usually ...
Cached Medicine News:Health News:Smoked Marijuana May Ease Chronic Nerve Pain 2Health News:Smoked Marijuana May Ease Chronic Nerve Pain 3Health News:Over 50? You probably prefer negative stories about young people 2Health News:Over 50? You probably prefer negative stories about young people 3Health News:Heart disorder hits national epidemic proportions 2Health News:Concussions in young athletes on the rise 2Health News:Concussions in young athletes on the rise 3Health News:New Migraine Gene Discovered 2Health News:New Migraine Gene Discovered 3Health News:New genomic marker for tuberculosis may help identify patients who will develop the disease 2Health News:New genomic marker for tuberculosis may help identify patients who will develop the disease 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: